[{"orgOrder":0,"company":"Scotmann Pharmaceuticals","sponsor":"Rawalpindi Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Scotmann Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College","highestDevelopmentStatusID":"8","companyTruncated":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College"},{"orgOrder":0,"company":"Scotmann Pharmaceuticals","sponsor":"Rawalpindi Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Scotmann Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College","highestDevelopmentStatusID":"10","companyTruncated":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College"},{"orgOrder":0,"company":"Scotmann Pharmaceuticals","sponsor":"University of Health Sciences Lahore","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Scotmann Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scotmann Pharmaceuticals \/ University of Health Sciences Lahore","highestDevelopmentStatusID":"10","companyTruncated":"Scotmann Pharmaceuticals \/ University of Health Sciences Lahore"},{"orgOrder":0,"company":"Scotmann Pharmaceuticals","sponsor":"Rawalpindi Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"PAKISTAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Sunnyd Stat","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scotmann Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College","highestDevelopmentStatusID":"8","companyTruncated":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College"}]

Find Clinical Drug Pipeline Developments & Deals by Scotmann Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 14, 2022

                          Lead Product(s) : Empagliflozin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : University of Health Sciences Lahore

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Vortioxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 03, 2021

                          Lead Product(s) : Vortioxetine Hydrobromide

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Rawalpindi Medical College

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Sunnyd Stat is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vitamin D Deficiency.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 03, 2021

                          Lead Product(s) : Sunnyd Stat

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Rawalpindi Medical College

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Apixaban is a HPAPI drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : HPAPI

                          Upfront Cash : Inapplicable

                          October 22, 2021

                          Lead Product(s) : Apixaban

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Rawalpindi Medical College

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank